CNAfingerprint, A biomarker for oxaliplatin-based chemotherapy response prediction in mCRC
We developed and validated a copy number alteration (CNA) based biomarker to predict the effectiveness of oxaliplatin-based regimen in mCRC patients. This machine learning model biomarker was developed retrospectively using competitively low-cost shallow sequencing data, the performance of CNA fingerprint has been validated in three independent test mCRC cohorts.
This data repository stores partial process data for model CNAfingerprint.
The model can be found in CNAfingerprint;
The details of train cohorts (Prediction Scores, Other Information) can be found in /data/Prescore_lable_train.rds;
The details of 3 test cohorts (Prediction Scores, Other Information) can be found in /data/all_test.csv;
The details of non-oxaliplatin cohorts can be found in /data/noOxa_cohort.rds;
If you want to reuse the code in this report, please note the license below should be followed.
The code is made available for non commercial research purposes only under the MIT. However, notwithstanding any provision of the MIT License, the software currently may not be used for commercial purposes without explicit written permission after contacting Jinyu Wangwangjy10@shanghaitech.edu.cn{.email} or Tiyu Taotaozy@shanghaitech.edu.cn{.email} or Xue-Song Liu liuxs@shanghaitech.edu.cn{.email}.